1.Epidural chloroma and spinal cord compression.
Hyun Jung KOH ; Jungwon BAEK ; Min Soo LEE ; Hue Jung PARK
Chinese Medical Journal 2019;132(7):853-855
Aged
;
Bone Marrow
;
diagnostic imaging
;
pathology
;
Epidural Space
;
diagnostic imaging
;
pathology
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
diagnostic imaging
;
pathology
;
Male
;
Sarcoma, Myeloid
;
diagnostic imaging
;
pathology
;
Spinal Cord Compression
;
diagnostic imaging
;
pathology
2.Factors Related to Decreased Bone Mineral Density in Childhood Cancer Survivors.
Yun Jung CHOI ; Sun Young PARK ; Won Kyoung CHO ; Jae Wook LEE ; Kyoung Soon CHO ; So Hyun PARK ; Seung Hoon HAHN ; Min Ho JUNG ; Nack Gyun CHUNG ; Bin CHO ; Byung Kyu SUH ; Hack Ki KIM
Journal of Korean Medical Science 2013;28(11):1632-1638
The risk of osteoporosis or osteopenia is known to increase after childhood cancer treatment. The purpose of this study was to evaluate patterns of bone mineral density (BMD) and to identify factors related to the decreased BMD in childhood cancer survivors. We studied 78 patients (34 boys, 44 girls) treated for childhood cancer. Twenty (25.7%) patients had lumbar BMD (LBMD) standard deviation score (SDS) lower than -2. Nineteen (24.4%) patients had femur neck BMD (FNBMD) SDS lower than -2. The patients treated with hematopoietic stem cell transplantation had lower LBMD SDS (-1.17 +/- 1.39 vs -0.43 +/- 1.33, P = 0.025). The risk of having LBMD SDS < -2 was higher in the patients treated with glucocorticoid (GC) for graft-versus-host disease (GVHD) (36.6% vs 13.5%; odds ratio [OR], 3.7; P = 0.020). In multivariate logistic regression analysis, longer duration of GC treatment for GVHD (OR, 1.12; 95% confidence interval [CI], 1.05-1.20) and lower body mass index (BMI) SDS (OR, 0.59; 95% CI, 0.36-0.95) were associated with decreased LBMD SDS. These findings suggest that prolonged GC use and reduction in BMI are risk factors for decreased BMD in childhood cancer survivors. Anticipatory follow-up and appropriate treatment are necessary, especially for the patients with risk factors.
Adolescent
;
Body Mass Index
;
Bone Density/*drug effects
;
Bone Diseases, Metabolic/*chemically induced
;
Child
;
Female
;
Glucocorticoids/*adverse effects/*therapeutic use
;
Graft vs Host Disease/drug therapy
;
Hematopoietic Stem Cell Transplantation/adverse effects
;
Hormones/blood
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology
;
Leukemia, Myeloid, Acute/pathology
;
Male
;
Osteoporosis/*chemically induced
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology
;
Risk Factors
;
Survivors
3.Clinical Characteristics of 75 Patients with Leukemia Cutis.
Yeon Soo KANG ; Hei Sung KIM ; Hyun Jeong PARK ; Jun Young LEE ; Hyung Ok KIM ; Baik Kee CHO ; Young Min PARK
Journal of Korean Medical Science 2013;28(4):614-619
Leukemia cutis (LC) is defined as a neoplastic leukocytic infiltration of the skin. Few clinical studies are available on recent trends of LC in Korea. The purpose of this study was to analyze the clinical features and prognosis of LC in Korea and to compare findings with previous studies. We performed a retrospective study of 75 patients with LC and evaluated the patients' age and sex, clinical features and skin lesion distribution according to the type of leukemia, interval between the diagnosis of leukemia and the development of LC, and prognosis. The male to female ratio was 2:1, and the mean age at diagnosis was 37.6 yr. The most common cutaneous lesions were nodules. The most commonly affected site was the extremities in acute myelocytic leukemia and chronic myelocytic leukemia except for acute lymphocytic leukemia. Compared with previous studies, there was an increasing tendency in the proportion of males and nodular lesions, and LC most often occurred in the extremities. The prognosis of LC was still poor within 1 yr, which was similar to the results of previous studies. These results suggest that there is a difference in the clinical characteristics and predilection sites according to type of leukemia.
Adult
;
Extremities/pathology
;
Female
;
Humans
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/mortality/pathology
;
Leukemia, Myeloid, Acute/*diagnosis/mortality/pathology
;
*Leukemic Infiltration
;
Male
;
Neoplasm Staging
;
Retrospective Studies
;
Skin/*pathology
4.Expression of eIF4E in patients with leukemia and its clinical significance.
Liang-Fang ZHU ; Xin-Ji CHEN ; Jian-Da HU
Journal of Experimental Hematology 2013;21(1):1-6
This study was aimed to compare the expression level of eIF4E in patients with leukemia and normal controls, and to explore its role in leukemogenesis. White blood cells were collected in 76 leukemia patients and 10 healthy volunteers. The mRNA and protein expressions of eIF4E were detected by QT-PCR and Western blot in 39 cases of acute myeloid leukemia (AML), 15 cases of chronic myeloid leukemia (CML), 22 cases of acute lymphocytic leukemia (ALL) and 10 healthy volunteers as normal controls. The results demonstrated that compared with normal controls, the absolute expression levels of eIF4E mRNA increased in patients with AML, ALL and CML in blastic phase (P < 0.05), but had no significant change between groups of CML in chronic and accelerated phase although some increasing in group of CML in accelerated phase. The relative expression level of eIF4E mRNA had no significant change in AML, ALL, CML groups except the two subtypes of leukemia M4 and M5. Furthermore, the protein expression level in group of CML in accelerated phase and blastic phase and all acute leukemia patients including AML and ALL were higher than that in normal controls (P < 0.05). It is concluded that although its mRNA relative expressions had no significant change in most leukemia patients, the absolute expression level of eIF4E mRNA and its protein expression is up-regulated in most leukemia patients, which may play an important role in leukemogenesis, so the eIF4E may be a promising target for leukemia therapy and eIF4E-targeted therapy may be an option especially for the relapse and refractory leukemia.
Adolescent
;
Adult
;
Aged
;
Case-Control Studies
;
Eukaryotic Initiation Factor-4E
;
genetics
;
metabolism
;
Female
;
Humans
;
Leukemia
;
genetics
;
metabolism
;
pathology
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
Leukemia, Myeloid, Acute
;
Male
;
Middle Aged
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
RNA, Messenger
;
genetics
;
Young Adult
5.Chromosomal translocation and malignant tumor.
Chinese Journal of Pathology 2011;40(2):138-140
Diagnosis, Differential
;
Female
;
Humans
;
Immunohistochemistry
;
In Situ Hybridization, Fluorescence
;
Leukemia, Myeloid, Chronic-Phase
;
genetics
;
Lymphoma
;
classification
;
diagnosis
;
pathology
;
Male
;
Neoplasms
;
genetics
;
metabolism
;
pathology
;
Oncogene Proteins
;
metabolism
;
Prognosis
;
Prostatic Neoplasms
;
genetics
;
Reverse Transcriptase Polymerase Chain Reaction
;
Translocation, Genetic
;
Tumor Suppressor Proteins
;
metabolism
6.Characteristics and clinical significance of CD73 expression in subtypes of leukemia.
Shi-Xuan ZHAO ; Hua-Mei ZHANG ; Shu-Xu DONG ; Jin-Hua LIU ; Zheng ZHOU ; Hui-Jun WANG ; Xiao-Fan ZHU ; Ying-Chang MI ; Yong-Xin RU
Journal of Experimental Hematology 2011;19(5):1141-1144
The study was purposed to investigate the expression of CD73 on bone marrow nucleated cells (BMMNC) in various leukemia subtypes and its relationship with cell differentiation of leukemia. Immunocytochemistry staining and Wright-Giemsa staining of BMMNC from 75 cases of leukemia, 11 cases of myelodysplastic syndrome (MDS), 13 cases of non-leukemic patients and 9 healthy adults were performed, and the CD73(+) ratio in BMMNC and its relationship with differentiation of leukemia cells were analyzed. The results showed that the ratios of CD73(+) in BMMNC of com-B ALL, pre-B ALL and PLL were significantly higher than those in B-CLL (p < 0.05). CD73(+) ratios in AML subtypes of M(1), M(2a), t (8; 21), t (15; 17), M(4) and M(5) were markedly higher than those in MDS respectively, but in M(6) and MDS were lower and had no statistical difference between them. CD73(+) ratios in T-ALL, B-CLL, M(6), MDS, non-leukemia patients and healthy adults were close to each other and all of them were lower than those in B-ALL and other AML subtypes. It is concluded that the expression of CD73 is associated with leukemia subtype, differentiation and development. The higher differentiation of leukemia cells, the lower of CD73 expression in myeloid and B lymphoid leukemia, but T-ALL does not meet this pattern.
5'-Nucleotidase
;
metabolism
;
Adolescent
;
Adult
;
Cell Differentiation
;
Humans
;
Leukemia
;
metabolism
;
pathology
;
Leukemia, Lymphocytic, Chronic, B-Cell
;
metabolism
;
Leukemia, Myeloid, Acute
;
metabolism
;
Myelodysplastic Syndromes
;
metabolism
;
Young Adult
7.Expression of CIAPIN1 gene in BMMNC of patients with leukemia.
Bin LI ; Qing-Hua LI ; Ya-Ni LIN ; Wei-Na JIN ; Tian-Xiang PANG
Journal of Experimental Hematology 2011;19(3):570-573
This study was aimed to investigate the expression level of CIAPIN1 mRNA in leukemia patients and explore its significance in leukemias. The fresh bone marrow was collected from 112 newly diagnosed leukemia patients, the total RNA was extracted by means of TRIzoL, the cDNA was synthesized, the expression of CIAPIN1 mRNA was detected by real-time quantitative PCR using β-actin as internal reference; 10 normal healthy persons were selected as controls. The results showed that the expression of CIAPIN1 mRNA was statistically higher in acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic phase chronic myeloid leukemia (CML) patients than that in normal persons (p < 0.05); but there was no statistical difference between chronic lymphocytic leukemia (CLL) and normal persons (p > 0.05). It is concluded that the CIAPIN1 gene higher expresses in MNC of newly diagnosed leukemia patients, up-regulation of CIAPIN1 expression may play an important role in pathogenesis of leukemia.
Adult
;
Bone Marrow Cells
;
metabolism
;
Case-Control Studies
;
Female
;
Gene Expression Regulation, Leukemic
;
Humans
;
Intracellular Signaling Peptides and Proteins
;
genetics
;
Leukemia
;
genetics
;
metabolism
;
pathology
;
Leukemia, Lymphocytic, Chronic, B-Cell
;
genetics
;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
;
genetics
;
Leukemia, Myeloid, Acute
;
genetics
;
Male
;
Middle Aged
;
Young Adult
8.Preliminary study of proteins related to blast crisis in chronic myeloid leukemia.
Hong-qian ZHU ; Xiao-li LIU ; Rong LI ; Qing-feng DU ; Song ZHANG ; Feng YAO ; Zhi LIU
Chinese Journal of Oncology 2009;31(9):655-659
OBJECTIVETo identify and compare the expression profiles of differential proteins between chronic phase and blast crisis in chronic myeloid leukemia (CML) by proteomic analysis, and screen the proteins related to blast crisis.
METHODSThe total cellular proteins from the bone marrow cells at chronic phase (CP) and blast crisis (BC) in CML were separated by two-dimensional polyacrylamide gel electrophoresis (2-DE) and analyzed with ImageMaster 5.0 software to screen the differential protein spots. Differential protein spots were identified by mass spectrometry for peptide mass fingerprint in combination with database searching from SWISS-PROT. Then 3 protein spots were selected to verify at protein and mRNA levels by Western blot and semi-quantitative RT-PCR, separately.
RESULTSComparing gel pages from CML-CP and CML-BC, the expression of 13 protein spots decreased and 25 protein spots increased significantly in CML-BC. Twenty differential protein spots were identified by mass spectrometry and 15 were successfully determined. The results of Western blotting were similar to those of 2-DE and showed a high expression of hnRNPK, annexin A1 and RhoA. Semi-quantitative RT-PCR analysis showed that there was no correlation between the protein expression changes and mRNA levels of hnRNPK, annexin A1 and RhoA.
CONCLUSIONA group of proteins associated with blast crisis are obtained and the results may provide clues for further research to elucidate the role of these proteins in CML-BC carcinogenesis and to develop potential associated biomarkers.
Adult ; Aged ; Annexin A1 ; genetics ; metabolism ; Blast Crisis ; genetics ; metabolism ; Female ; Gene Expression Profiling ; Heterogeneous-Nuclear Ribonucleoprotein K ; Humans ; Leukemia, Myeloid, Chronic-Phase ; genetics ; metabolism ; pathology ; Male ; Middle Aged ; Proteomics ; methods ; RNA, Messenger ; metabolism ; Ribonucleoproteins ; genetics ; metabolism ; Young Adult ; rhoA GTP-Binding Protein ; genetics ; metabolism
9.Hydroxyurea Induced Perimalleolar Ulcers.
Kavitha SARAVU ; Praveen VELAPPAN ; Naik LAKSHMI ; Barkur Ananthakrishna SHASTRY ; Joseph THOMAS
Journal of Korean Medical Science 2006;21(1):177-179
Hydroxyurea (HU) is an antineoplastic drug commonly used to treat chronic myeloproliferative disorders. Common dermatological side effects include hyperpigmentation, scaling, erythema, alopecia, desquamation of face and hands. Leg ulceration following HU therapy is less common and very few cases have been reported so far. Objective of this paper is to increase the awareness of hydroxyurea induced leg ulcers which will aid in the early diagnosis and appropriate treatment. The first case was a chronic myeloid leukemia (CML) patient on HU 1.5 g/day for 5 yr, who had bilateral painful perimalleolar ulcers for 6 months. The second case was a CML patient on HU 1.5 g/day for 3 yr who developed bilateral lateral malleolar ulcers. Third case was a polycythemia vera (PV) patient on HU 1 g/day for 5 yr who presented with painful medial malleolar ulcer of 2 months. The last case of our report was an elderly PV patient on HU 1.5 g/day for 2 yr and presented with lateral malleolar ulcer which persisted on reducing the dose of HU. In all the 4 cases the ulcers healed on stopping HU. Our report confirms the association of chronic hydroxyurea therapy and perimalleolar ulcers which respond promptly after discontinuation of the drug. The heightened awareness among the physicians will promote early diagnosis and prompt relief from the agonizing ulcers.
Aged
;
Ankle
;
Antineoplastic Agents/adverse effects/therapeutic use
;
Humans
;
Hydroxyurea/*adverse effects/therapeutic use
;
Leg Ulcer/*chemically induced/pathology/therapy
;
Leukemia, Myeloid, Chronic/drug therapy
;
Male
;
Middle Aged
;
Phlebotomy
;
Polycythemia Vera/drug therapy
;
Wound Healing
10.A Case of Leukemic Pleural Infiltration in Atypical Chronic Myeloid Leukemia.
Hyun Woo KIM ; Sung Sook LEE ; Min Hee RYU ; Jae Lyun LEE ; Heung Moon CHANG ; Tae Won KIM ; Hyun Sook CHI ; Woo Kun KIM ; Jung Shin LEE ; Yoon Koo KANG
Journal of Korean Medical Science 2006;21(5):936-939
Pleural effusion in chronic myeloid leukemia (CML) is poorly understood and rarely reported in the literature. When the pleural effusion is caused by leukemic pleural infiltration, the differential white blood cell count of the effusion is identical to that of the peripheral blood, and the fluid cytology reveals leukemic blasts. We report here a case of bilateral pleural involvement of atypical CML in an 83-yr old male diagnosed with pancreatic cancer with abdominal wall metastasis and incidental peripheral leukocytosis. Based on bone marrow examination, chromosome analysis and polymerase chain reaction he was diagnosed with Philadelphia chromosome negative, BCR/ABL gene rearrangement negative CML. Following 3 months of treatment with gemcitabine for pancreatic cancer, he developed bilateral pleural effusions. All stages of granulocytes and a few blasts were present in both the pleural fluid and a peripheral blood smear. After treatment with hydroxyurea and pleurodesis, the pleural effusion resolved.
Pleural Effusion/*etiology/pathology
;
Male
;
Leukemic Infiltration/*pathology
;
Leukemia, Myeloid, Chronic/complications/*pathology
;
Humans
;
Aged, 80 and over
;
Aged

Result Analysis
Print
Save
E-mail